NO20075155L - Fremgangsmater for behandling av medikamentmisbruk og -avhengighet. - Google Patents

Fremgangsmater for behandling av medikamentmisbruk og -avhengighet.

Info

Publication number
NO20075155L
NO20075155L NO20075155A NO20075155A NO20075155L NO 20075155 L NO20075155 L NO 20075155L NO 20075155 A NO20075155 A NO 20075155A NO 20075155 A NO20075155 A NO 20075155A NO 20075155 L NO20075155 L NO 20075155L
Authority
NO
Norway
Prior art keywords
methods
addiction
compositions
treating
drug abuse
Prior art date
Application number
NO20075155A
Other languages
English (en)
Norwegian (no)
Inventor
Sanjay Sabnani
Donald Wesson
Josseph Dunn
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of NO20075155L publication Critical patent/NO20075155L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20075155A 2005-04-07 2007-10-10 Fremgangsmater for behandling av medikamentmisbruk og -avhengighet. NO20075155L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66903305P 2005-04-07 2005-04-07
US72901305P 2005-10-21 2005-10-21
US72897905P 2005-10-21 2005-10-21
PCT/US2006/013099 WO2006110557A2 (en) 2005-04-07 2006-04-07 Methods for the treatment of substance abuse and dependence

Publications (1)

Publication Number Publication Date
NO20075155L true NO20075155L (no) 2008-01-07

Family

ID=37087555

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20075155A NO20075155L (no) 2005-04-07 2007-10-10 Fremgangsmater for behandling av medikamentmisbruk og -avhengighet.
NO20075161A NO20075161L (no) 2005-04-07 2007-10-10 Fremgangsmate for behandling av angstrelaterte lidelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20075161A NO20075161L (no) 2005-04-07 2007-10-10 Fremgangsmate for behandling av angstrelaterte lidelser

Country Status (12)

Country Link
US (3) US20080207601A1 (pt)
EP (3) EP1868593A2 (pt)
JP (3) JP2008538748A (pt)
KR (2) KR20080004580A (pt)
AU (3) AU2006235318A1 (pt)
BR (2) BRPI0610693A2 (pt)
CA (3) CA2604887A1 (pt)
CR (2) CR9410A (pt)
IL (2) IL186447A0 (pt)
MX (2) MX2007012355A (pt)
NO (2) NO20075155L (pt)
WO (3) WO2006110642A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
US8586634B2 (en) 2007-06-15 2013-11-19 University Of Florida Research Foundation, Inc. Therapeutic compounds
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
ITRM20080436A1 (it) * 2008-08-06 2010-02-07 Francesco Marrosu Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita'
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
WO2010094074A1 (en) * 2009-02-20 2010-08-26 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20120295893A1 (en) * 2009-12-14 2012-11-22 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
AU2011279557B2 (en) * 2010-07-16 2018-09-27 Verita Research Pte Ltd Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
DK2935307T3 (en) * 2012-12-18 2018-07-30 Univ Washington NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
JP6715830B2 (ja) * 2014-06-26 2020-07-01 ザ・ジョンズ・ホプキンス・ユニバーシティ 過敏性腸症候群および末梢神経系の他の病気の治療のための末梢限局性ｇａｂａポジティブアロステリックモジュレーター
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
US20180050005A1 (en) * 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
US10933014B2 (en) * 2017-01-09 2021-03-02 Asarina Pharma Ab Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
CA3083850A1 (en) * 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
KR101898814B1 (ko) 2017-09-07 2018-09-13 백창목 도어 개폐용 도어록
WO2019055942A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING OPIOID TOLERANCE
WO2019055939A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING SYMPTOMS ASSOCIATED WITH OPIOID WEANING
US12414956B2 (en) 2017-09-20 2025-09-16 Calista Capital, Llc Method for smoking cessation
US10966988B2 (en) * 2017-09-20 2021-04-06 Calista Capital, Llc Method for smoking cessation
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
CN111918657A (zh) * 2018-04-05 2020-11-10 阿沙里那制药有限公司 用于治疗物质戒断障碍的gaba-a拮抗剂
EP3761979A4 (en) * 2018-04-06 2021-06-30 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT SUBSTANCE ABUSE
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
US20220152044A1 (en) * 2019-03-14 2022-05-19 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system
AU2020335372B2 (en) 2019-08-26 2025-07-03 Period Pill Bv Treatment of menstrual cycle-induced symptoms
US12233070B2 (en) 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
CN121695144A (zh) * 2020-11-27 2026-03-20 特雷泽制药私人有限公司 包含氟马西尼和纳曲酮的组合物及其使用方法
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
US5521181A (en) * 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
IT1274481B (it) * 1995-05-12 1997-07-17 Indena Spa Composizioni farmaceutiche per il trattamento della alcol-dipendenza
BR9812144A (pt) * 1997-08-28 2000-07-18 Janus Pharmaceuticals Inc Antagonistas da atividade de androgen como terapias para anorexia, anorexia nervosa e distúrbios caracterizados por uma condiçao de baixo peso patológica
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO1999061014A2 (en) 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
AU7331300A (en) * 1999-08-27 2001-03-26 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
US20020173495A1 (en) * 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
NZ539400A (en) 2001-01-17 2006-04-28 Hythiam Inc Use of flumazenil in developing a drug for the treatment of alcohol dependence
MXPA03007281A (es) 2001-02-15 2005-01-25 Hythiam Inc Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la dependencia de cocaina.
GB0311859D0 (en) * 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
PT1691811E (pt) * 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
MX2007012355A (es) 2008-01-16
AU2006235234A1 (en) 2006-10-19
EP1868432A2 (en) 2007-12-26
KR20080004580A (ko) 2008-01-09
US20080207601A1 (en) 2008-08-28
WO2006110557A3 (en) 2009-04-16
EP1901727A4 (en) 2009-11-11
BRPI0610693A2 (pt) 2016-11-22
AU2006235257B2 (en) 2010-11-04
EP1868593A2 (en) 2007-12-26
IL186447A0 (en) 2008-08-07
US20080280885A1 (en) 2008-11-13
NO20075161L (no) 2008-01-07
AU2006235257A1 (en) 2006-10-19
US20080255097A1 (en) 2008-10-16
CR9413A (es) 2008-01-21
WO2006110642A2 (en) 2006-10-19
MX2007012353A (es) 2008-01-16
WO2006110557A2 (en) 2006-10-19
CA2603519A1 (en) 2006-10-19
WO2006110642A3 (en) 2009-04-23
CA2603533A1 (en) 2006-10-19
WO2006110580A2 (en) 2006-10-19
EP1901727A2 (en) 2008-03-26
WO2006110580A3 (en) 2007-08-16
IL186450A0 (en) 2008-01-20
KR20080004581A (ko) 2008-01-09
JP2008535852A (ja) 2008-09-04
CA2604887A1 (en) 2006-10-19
JP2008535850A (ja) 2008-09-04
BRPI0609744A2 (pt) 2010-04-27
EP1868432A4 (en) 2009-11-04
US8012958B2 (en) 2011-09-06
JP2008538748A (ja) 2008-11-06
AU2006235318A1 (en) 2006-10-19
CR9410A (es) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2006110557A3 (en) Methods for the treatment of substance abuse and dependence
Seifi et al. The effect of lavender essential oil on anxiety level in patients undergoing coronary artery bypass graft surgery: A double-blinded randomized clinical trial
Zhu et al. Green tea polyphenols produce antidepressant-like effects in adult mice
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
Makhlouf et al. Depression and erectile dysfunction
WO2006054057A3 (en) New use for cannabinoid
BRPI0518011A (pt) uso de tetraidrocanabidivarina, métodos para o tratamento de uma doença ou condição e para cosmeticamente beneficiar a perda de peso, e, uso de um antagonista do receptor de canabinóide neutro
Rosenberg et al. Paroxetine open‐label treatment of pediatric outpatients with obsessive‐compulsive disorder
NO20074117L (no) Fremgangsmater og sammensetninger for a behandle diabetes, metabolske sykdommer og tilstander
WO2006023703A3 (en) Method for treating sleep related breathing disorders
NO20084567L (no) Polymorfe former av (2S) - (4E) -N-metyl-5-(3-isopropoksypyridin)yl]-4-penten-2-amin for behandling av sykdommer i sentralnervesystemet
WO2007143607A3 (en) Method of treating atrophic vaginitis
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
Chen et al. Electroacupuncture reduces postoperative pain and analgesic consumption in patients undergoing thoracic surgery: a randomized study
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
NO20064924L (no) Eksperimenteringssikker doseringsform som innbefatter an adsorbent og et skadelig middel
BRPI0513840A (pt) método para controle de obesidade em um paciente mamìfero necessitado de um tal tratamento, método para tratamento de obesidade em um paciente humano diabético e sendo tratado com uma droga receitada para diabetes, método para tratamento de diabetes mellitus em um paciente mamìfero necessitado de um tal tratamento para controle da diabetes mellitus, método para tratamento ou controle de hiperglicemia em um paciente mamìfero necessitado de um tal tratamento, composição para uso no tratamento de obesidade, diabetes, ou hiperglicemia como doença, método para tratamento ou controle de distúrbios lipìdicos, hiperlipidemia, ou baixo nìvel de hdl em um paciente mamìfero necessitado do mesmo, método para tratamento ou controle de hipercolesterolemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de hipergligeridemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de dislipidemia e/ou baixo nìvel de hdl colesterol em um paciente mamìfero necessitado de um tal tratamento, e método para tratamento de arteriosclerose em um paciente mamìfero necessitado de um tal tratamento
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
Ashamalla et al. Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy
WO2008036448A3 (en) Composition and method of treating a sore throat
CR8850A (es) Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales
BRPI0512869A (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente
NO20081835L (no) Behandlingsmetoder ved bruk av oksytocin receptoragonister
Zandi et al. Helicobacter pylori and rosacea.
IL202270A0 (en) Therapeutic pyrazoloquinoline derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application